导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.77% | 1761/4773 |
| 近一周 | -1.82% | 2939/5465 |
| 近一月 | -2.52% | 1720/5421 |
| 近一季 | -4.63% | 1857/5231 |
| 近半年 | 0.87% | 1243/4920 |
| 近一年 | 6.70% | 1567/4394 |
| 近两年 | 51.28% | 1452/2954 |
| 近三年 | 35.21% | 908/2253 |
| 成立以来 | 95.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.94% 2572/4961 |
11.82% 2289/5312 |
- - |
- - |
| 2025 | 21.88% 2013/4813 |
-0.70% 2368/3635 |
2.58% 1479/4076 |
17.90% 2402/4524 |
1.49% 1355/4813 |
| 2024 | 15.92% 864/3463 |
4.59% 444/2808 |
-0.36% 745/3014 |
14.35% 1996/3129 |
-2.73% 2167/3463 |
| 2023 | -6.99% 886/2656 |
4.80% 867/2280 |
-3.33% 774/2385 |
-1.83% 584/2515 |
-6.48% 1795/2655 |
| 2022 | -18.49% 716/2207 |
-12.16% 579/1919 |
5.03% 946/2016 |
-12.59% 737/2113 |
1.09% 1390/2208 |
| 2021 | -3.48% 907/1822 |
-1.57% 516/1255 |
4.82% 843/1330 |
-5.17% 783/1466 |
-1.35% 1355/1822 |
| 2020 | 45.84% 216/1250 |
-6.15% 460/1028 |
17.80% 360/1067 |
15.54% 209/1164 |
14.17% 294/1184 |
| 2019 | 38.71% 302/1092 |
26.05% 428/754 |
0.98% 147/804 |
0.52% 511/850 |
8.40% 320/918 |
| 2018 | -19.75% 176/834 |
- - |
- - |
- - |
-11.19% 258/691 |
| 2017 | 18.75% 205/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中金沪深300C VS. 长安沪深300非周期A(740101) |